Keros Therapeutics, Inc. cotiza a 11.23 USD y tiene una capitalización bursátil de $223M. En los últimos 12 meses ha facturado $15M con un margen de flujo de caja libre del 43.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap an…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.45 | $-1.21 | $-0.86 |
| Estimado | $-0.88 | $-1.24 | $-0.92 | $-0.45 |
| Sorpresa | — | -16.9% | -31.5% | -91.1% |
| Métrica | KROS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | 27.7% | -38.6% | +66.3% |
| Net Margin | 35.7% | -33.6% | +69.2% |
| FCF Margin | 43.5% | -13.9% | +57.3% |
| ROE | 28.7% | -40.4% | +69.1% |
| ROA | 25.7% | -32.0% | +57.8% |
| Current Ratio | 15.45 | 2.84 | +12.61 |
| Debt / Equity | — | 0.28 | — |